{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:31:41Z","timestamp":1773808301626,"version":"3.50.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Pediatr Emer Care"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Convulsive status epilepticus (CSE) is the most common neurological emergency in children. It is a frequent cause of admission to pediatric intensive care units and is associated with significant short- and long-term morbidity. Management of CSE is a step-wise approach: first-line antiseizure agents (typically benzodiazepines) followed by a second-line agent before deeper anesthesia usually accompanied by intubation and ventilation. Current guidelines in the United Kingdom specify phenytoin as the second-line agent of choice for CSE. Two recent large international randomized controlled trials compared the efficacy of phenytoin with that of another second-line agent levetiracetam. Both studies found levetiracetam to be noninferior to phenytoin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted an online survey of clinicians across 67 emergency departments that treat children and 29 pediatric intensive care units in the United Kingdom and Ireland to assess their current and preferred second-line agents for treating pediatric CSE in light of recently published evidence. The survey was distributed via the Pediatric Emergency Research in United Kingdom and Ireland network and the Pediatric Critical Care Society.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We found that although most clinicians use phenytoin, as per current guidelines, they seek greater flexibility in choice of second-line agent, with levetiracetam being the preferred alternative to phenytoin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>To facilitate use of levetiracetam for treatment of CSE in pediatrics, it should be included as a second-line agent in addition to phenytoin in the next update of the National Institute for Health and Care Excellence and other United Kingdom clinical guidelines.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/pec.0000000000002745","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T12:03:33Z","timestamp":1651752213000},"page":"247-252","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Survey About Second-Line Agents for Pediatric Convulsive Status Epilepticus"],"prefix":"10.1097","volume":"39","author":[{"given":"Marguerite","family":"Tyson","sequence":"first","affiliation":[{"name":"Paediatric Intensive Care Unit, Great Ormond Street Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Trenear","sequence":"additional","affiliation":[{"name":"Royal London Hospital, Barts Health Trust NHS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Skellett","sequence":"additional","affiliation":[{"name":"Paediatric Intensive Care Unit, Great Ormond Street Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Maconochie","sequence":"additional","affiliation":[{"name":"Paediatric Emergency Medicine, Imperial College Healthcare Trust NHS, Faculty of Medicine Imperial College, London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niall","family":"Mullen","sequence":"additional","affiliation":[{"name":"Department of Paediatric Emergency Medicine, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"bib1-20250504","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.nic.2018.03.007","article-title":"Neurologic emergencies in pediatric patients including accidental and nonaccidental trauma","volume":"28","year":"2018","journal-title":"Neuroimaging Clin N Am"},{"key":"bib2-20250504","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.nic.2010.07.008","article-title":"Pediatric central nervous system emergencies","volume":"20","year":"2010","journal-title":"Neuroimaging Clin N Am"},{"key":"bib3-20250504","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/j.1528-1167.2007.01175.x","article-title":"The epidemiology of convulsive status epilepticus in children: a critical review","volume":"48","year":"2007","journal-title":"Epilepsia"},{"key":"bib4-20250504","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.58.7.1070","article-title":"Incidence and mortality of generalized convulsive status epilepticus in California","volume":"58","year":"2002","journal-title":"Neurology"},{"key":"bib5-20250504","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(06)69043-0","article-title":"Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study","volume":"368","year":"2006","journal-title":"Lancet"},{"key":"bib6-20250504","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.seizure.2018.08.021","article-title":"The burden of pediatric status epilepticus: epidemiology, morbidity, mortality, and costs","volume":"68","year":"2019","journal-title":"Seizure"},{"key":"bib7-20250504","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12028-008-9061-3","article-title":"Development of a pediatric neurocritical care service","volume":"10","year":"2009","journal-title":"Neurocrit Care"},{"key":"bib8-20250504","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/adc.2006.107516","article-title":"Outcome of convulsive status epilepticus: a review","volume":"92","year":"2007","journal-title":"Arch Dis Child"},{"key":"bib9-20250504","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(19)30724-X","article-title":"Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"bib10-20250504","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/S0140-6736(19)30722-6","article-title":"Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"bib11-20250504","article-title":"Epilepsies: diagnosis and management","year":"2012","journal-title":"Clinical guideline [CG137]"},{"key":"bib12-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archneur.1973.00490190019001","article-title":"Physiology of status epilepticus in primates","volume":"28","year":"1973","journal-title":"Arch Neurol"},{"key":"bib13-20250504","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1474-4422(06)70546-4","article-title":"Outcome of paediatric convulsive status epilepticus: a systematic review","volume":"5","year":"2006","journal-title":"Lancet Neurol"},{"key":"bib14-20250504","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1212\/WNL.0000000000000710","article-title":"Convulsive status epilepticus and health-related quality of life in children with epilepsy","volume":"83","year":"2014","journal-title":"Neurology"},{"key":"bib15-20250504","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/epi.14515","article-title":"Long-term outcomes of status epilepticus: a critical assessment","volume":"59","year":"2018","journal-title":"Epilepsia"},{"key":"bib17-20250504","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1212\/WNL.44.8.1403","article-title":"The secondarily generalized tonic-clonic seizure: a videotape analysis","volume":"44","year":"1994","journal-title":"Neurology"},{"key":"bib18-20250504","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/j.1528-1167.2006.00622.x","article-title":"How long do most seizures last? A systematic comparison of seizures recorded in the epilepsy monitoring unit","volume":"47","year":"2006","journal-title":"Epilepsia"},{"key":"bib19-20250504","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ana.1018","article-title":"How long do new-onset seizures in children last?","volume":"49","year":"2001","journal-title":"Ann Neurol"},{"key":"bib20-20250504","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S2352-4642(17)30174-8","article-title":"Long-term prognosis after childhood convulsive status epilepticus: a prospective cohort study","volume":"2","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"bib21-20250504","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus\u2014report of the ILAE Task Force on Classification of Status Epilepticus","volume":"56","year":"2015","journal-title":"Epilepsia"},{"key":"bib22-20250504","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0140-6736(20)30611-5","article-title":"Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"bib23-20250504","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3988\/jcn.2019.15.4.468","article-title":"Clinical efficacy and safety of injectable levetiracetam versus phenytoin as second-line therapy in the management of generalized convulsive status epilepticus in children: an open-label randomized controlled trial","volume":"15","year":"2019","journal-title":"J Clin Neurol"},{"key":"bib24-20250504","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12098-020-03221-2","article-title":"Clinical effectiveness of levetiracetam compared to fosphenytoin in the treatment of benzodiazepine refractory convulsive status epilepticus","volume":"87","year":"2020","journal-title":"Indian J Pediatr"},{"key":"bib25-20250504","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s13312-020-1755-4","article-title":"Comparison of phenytoin, valproate and levetiracetam in pediatric convulsive status epilepticus: a randomized double-blind controlled clinical trial","volume":"57","year":"2020","journal-title":"Indian Pediatr"},{"key":"bib26-20250504","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.4103\/jfmpc.jfmpc_750_19","article-title":"Levetiracetam versus phenytoin in children with status epilepticus","volume":"8","year":"2019","journal-title":"J Family Med Prim Care"},{"key":"bib29-20250504","article-title":"Advanced Paediatric life support (APLS) Australia","year":"2020","journal-title":"Status epilepticus Management"},{"key":"bib30-20250504","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.resuscitation.2021.02.015","article-title":"European Resuscitation Council Guidelines 2021: paediatric life support","volume":"161","year":"2021","journal-title":"Resuscitation"}],"container-title":["Pediatric Emergency Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PEC.0000000000002745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T18:02:47Z","timestamp":1746381767000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PEC.0000000000002745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/pec.0000000000002745","relation":{},"ISSN":["1535-1815","0749-5161"],"issn-type":[{"value":"1535-1815","type":"electronic"},{"value":"0749-5161","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,5]]}}}